Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Regulation category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Arrowhead Pharmaceuticals, Inc. faces a significant business risk if the FDA or comparable foreign regulatory authorities approve generic versions of their product REDEMPLO, or any other potential products that receive marketing approval, without granting appropriate periods of data or market exclusivity. The introduction of generic drugs, which are typically less costly to produce and can be sold at lower prices, could lead to a substantial loss of sales for REDEMPLO. This competition could materially and adversely impact the company’s future revenue, profitability, and cash flows, limiting their ability to recoup investments made in these products. The risk is heightened if REDEMPLO or other product candidates are not afforded the necessary non-patent exclusivity periods, which are crucial for maintaining market share against generic competitors.
The average ARWR stock price target is $49.00, implying -15.09% downside potential.
To learn more about Arrowhead Pharmaceuticals, Inc.’s risk factors, click here.